title: Toward personalized medicine in the neuropsychiatric field.
abstract: There are great expectations for the personalized medicine approach to address the therapeutic needs of patients in the twenty-first century. Advances in human genome science and molecular innovations in neuroscience have encouraged the pharmaceutical industry to focus beyond broad spectrum population therapeutics--the driving force behind the "blockbuster" product concept--to personalized medicine. For central nervous system (CNS) therapeutics, repeated failures in converting scientific discoveries to clinical trial successes and regulatory approvals have precipitated a drug pipeline crisis and eroded confidence in the industry. This chapter describes how innovations in genomics and translational medicine can impact the future of neuropsychiatry and deconvolute the complexity of psychiatric diseases from symptoms biology. A targeted and consistent investment is needed to restore confidence in translating science into clinical success.
authors: AstraZeneca Pharmaceuticals, External Science, CNS-Pain Innovative Medicine Unit, Wilmington, Delaware, USA.
authors: Erik H F
authors: EH
authors: Wong
authors: Jayne C
authors: JC
authors: Fox
authors: Mandy Y M
authors: MY
authors: Ng
authors: Chi-Ming
authors: CM
authors: Lee
mesh_terms: D015195:Drug Design; D004345:Drug Industry / Q000379:methods* / Q000639:trends; D006801:Humans; D019965:Neurocognitive Disorders / Q000188:drug therapy* / Q000235:genetics; D009480:Neuropharmacology / Q000379:methods / Q000639:trends; D058027:Neuropsychiatry / Q000379:methods* / Q000639:trends; D010597:Pharmacogenetics / Q000379:methods* / Q000639:trends; D057285:Precision Medicine / Q000379:methods* / Q000639:trends; D057170:Translational Research, Biomedical / Q000379:methods* / Q000639:trends